JASPER THERAPEUTICS INC

Company Overview

Jasper Therapeutics is a clinical‑stage biotechnology company developing briquilimab, an anti–c‑Kit monoclonal antibody aimed at depleting mast cells for chronic mast‑cell driven diseases (CSU, CIndU, allergic asthma) and as a one‑time conditioning agent for SCID re‑transplant. The company is R&D‑centric (≈64 employees) with no internal manufacturing or commercial sales force, relying on third‑party CMOs (e.g., Lonza, PCI) and in‑licensed patents from Amgen/Stanford alongside its own patent applications. Business cadence is driven by clinical enrollment, data readouts, manufacturing lot availability and regulatory interactions; recent operational stressors include a lot investigation that halted enrollment in one study and a mid‑2025 reorganization reducing headcount ~50%. Management reports widening losses, constrained liquidity and a continued need to raise capital to fund ongoing trials and commercialization planning.

Executive Compensation Practices

Compensation is likely equity‑heavy and milestone‑driven: the company recognized $6.6 million of stock‑based compensation in 2024, and management has expanded payroll to support clinical programs (R&D and G&A increases noted in filings). Given limited cash (material doubt about going concern) and the clinical‑stage profile, executives are typically paid with modest cash salaries supplemented by stock options/RSUs, performance or milestone bonuses tied to clinical readouts, regulatory milestones, financing events or partnering deals, and retention/acceleration features (especially during reorganizations). Recent workforce reductions and expected severance obligations also affect near‑term cash compensation and may trigger option vesting/acceleration provisions. The materiality of stock‑based compensation in the company’s financials means equity awards materially influence reported losses and dilution considerations for shareholders.

Insider Trading Considerations

Insider transactions at Jasper should be watched relative to clinical milestones, the lot‑investigation outcomes, enrollment pauses/resumptions and financing events (active S‑3 shelf/ATM and recent equity raises), since these are high‑information events that can materially move the stock. Small company size and concentrated insider ownership can make insider sales or option exercises more impactful; insiders may use registered offerings or ATM programs for liquidity, and same‑day cashless exercises or sales are common in this setting. Expect routine blackout windows around material nonpublic trial data, FDA interactions or manufacturing/inspection developments and widespread use of Rule 10b5‑1 plans; monitor Form 4 filings closely for timing relative to the company’s key clinical and financing catalysts. Regulatory factors (BLA pathway, manufacturing inspections, license milestone payments) create additional windows of material nonpublic information that increase legal and reputational risk for untimely insider trades.